D. Debieuvre

6.3k total citations
160 papers, 1.8k citations indexed

About

D. Debieuvre is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, D. Debieuvre has authored 160 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Pulmonary and Respiratory Medicine, 97 papers in Oncology and 28 papers in Epidemiology. Recurrent topics in D. Debieuvre's work include Lung Cancer Treatments and Mutations (86 papers), Lung Cancer Diagnosis and Treatment (48 papers) and Lung Cancer Research Studies (47 papers). D. Debieuvre is often cited by papers focused on Lung Cancer Treatments and Mutations (86 papers), Lung Cancer Diagnosis and Treatment (48 papers) and Lung Cancer Research Studies (47 papers). D. Debieuvre collaborates with scholars based in France, United States and United Kingdom. D. Debieuvre's co-authors include Élisabeth Quoix, Jean-Luc Breton, B. Milleron, Denis Moro‐Sibilot, A Depierre, M Grivaux, Olivier Molinier, Jean-Louis Pujol, É. Lemarié and Gérard Zalcman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

D. Debieuvre

139 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Debieuvre France	22	1.2k	1.0k	361	224	167	160	1.8k
Jeong‐Seon Ryu South Korea	22	772 0.7×	558 0.5×	563 1.6×	136 0.6×	260 1.6×	121	1.5k
Tatsuhiko Kashii Japan	18	761 0.7×	613 0.6×	286 0.8×	66 0.3×	140 0.8×	78	1.3k
Thomas L. Riley United States	15	815 0.7×	492 0.5×	160 0.4×	78 0.3×	143 0.9×	27	1.5k
Huakang Tu United States	23	384 0.3×	339 0.3×	301 0.8×	110 0.5×	178 1.1×	61	1.2k
Vesna Zadnik Slovenia	18	331 0.3×	915 0.9×	201 0.6×	146 0.7×	160 1.0×	56	1.4k
I. Hodson Canada	11	613 0.5×	1000 1.0×	342 0.9×	522 2.3×	85 0.5×	23	1.7k
Adam Lam United States	15	901 0.8×	217 0.2×	248 0.7×	128 0.6×	80 0.5×	35	1.4k
Muneer J. Al‐Husseini Egypt	15	395 0.3×	629 0.6×	297 0.8×	155 0.7×	234 1.4×	38	1.3k
Cheng‐Hwai Tzeng Taiwan	24	366 0.3×	485 0.5×	340 0.9×	170 0.8×	77 0.5×	90	1.3k
Carmel Stock United Kingdom	15	807 0.7×	557 0.5×	284 0.8×	200 0.9×	45 0.3×	34	1.5k

Countries citing papers authored by D. Debieuvre

Since Specialization

Citations

This map shows the geographic impact of D. Debieuvre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Debieuvre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Debieuvre more than expected).

Fields of papers citing papers by D. Debieuvre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Debieuvre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Debieuvre. The network helps show where D. Debieuvre may publish in the future.

Co-authorship network of co-authors of D. Debieuvre

This figure shows the co-authorship network connecting the top 25 collaborators of D. Debieuvre. A scholar is included among the top collaborators of D. Debieuvre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Debieuvre. D. Debieuvre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chouaïd, C., D. Debieuvre, Clarisse Audigier-Valette, et al.. (2025). Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis. Frontiers in Oncology. 15. 1526931–1526931. 1 indexed citations

Gobbini, Élisa, Mamadou Diallo, Dominique Pasquier, et al.. (2025). Clinical characteristics and management of long survivors in extensive stage small cell lung cancer. Lung Cancer. 202. 108499–108499.

Debieuvre, D.. (2025). Épidémiologie du cancer du poumon : évolution des vingt dernières années. Bulletin du Cancer. 112(3). 3S3–3S15.

Couraud, S., Olivier Molinier, Virginie Levrat, et al.. (2025). Outcomes of cannabis smoking in patients with lung cancer: findings from KBP-CPHG-2020. Respiratory Medicine and Research. 88. 101174–101174. 1 indexed citations

Leblanc, Serge, Michaël Génin, Florent Occelli, et al.. (2024). Association épidémiologique entre pollution et altérations oncogéniques dans le cancer du poumon. Revue des Maladies Respiratoires Actualités. 16(1). 19–20.

Audigier-Valette, Clarisse, Thomas Filleron, D. Debieuvre, et al.. (2023). Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy. Respiratory Medicine and Research. 84. 101012–101012. 5 indexed citations

Heudel, Pierre-Étienne, Anne Montfort, D. Debieuvre, et al.. (2023). Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 182. 107280–107280.

Debieuvre, D., Xavier Quantin, Nicolas Girard, et al.. (2023). 1396P HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France. Annals of Oncology. 34. S799–S799. 1 indexed citations

Chouaïd, C., Michael Thomas, D. Debieuvre, et al.. (2022). Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. Cancers. 14(24). 6148–6148. 3 indexed citations

10.

Blons, Hélène, Jean‐Philippe Merlio, D. Debieuvre, et al.. (2020). PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. Lung Cancer. 151. 69–75. 7 indexed citations

11.

Debieuvre, D., et al.. (2020). Embolie gazeuse cérébrale : une complication rare de la fibroscopie bronchique souple. Revue des Maladies Respiratoires. 37(8). 662–665. 1 indexed citations

12.

Lièvre, Astrid, Anthony Turpin, Isabelle Laure Ray-Coquard, et al.. (2020). 1673MO The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management. Annals of Oncology. 31. S993–S993. 1 indexed citations

13.

Bennouna, Jaafar, Nicolas Girard, Clarisse Audigier-Valette, et al.. (2019). Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. Clinical Lung Cancer. 21(1). e10–e14. 19 indexed citations

14.

Grivaux, M, François Goupil, Bernard Asselain, et al.. (2017). Stratégies thérapeutiques les 2 premières années après un diagnostic de cancer du poumon. ESCAP-2011-CPHG, étude en situation réelle réalisée dans les hôpitaux généraux français. Revue des Maladies Respiratoires. 34(9). 991–999. 7 indexed citations

15.

Leduc, Charlotte, Hélène Blons, Benjamin Besse, et al.. (2016). Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Annals of Oncology. 27. vi416–vi416. 2 indexed citations

16.

Couraud, S., D. Debieuvre, L. Moreau, et al.. (2015). No impact of passive smoke on the somatic profile of lung cancers in never-smokers. European Respiratory Journal. 45(5). 1415–1425. 19 indexed citations

17.

Debieuvre, D., Chrystèle Locher, Jacky Créquit, et al.. (2013). Major changes in men with non-small-cell lung cancer (NSCLC) in 10 years: The KBP-2000-CPHG and KBP-2010-CPHG cohorts. European Respiratory Journal. 42(Suppl 57). 1819–1819.

18.

Fraipont, Florence de, Guénaëlle Levallet, Christian Créveuil, et al.. (2012). An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial. Clinical Cancer Research. 18(10). 2976–2986. 46 indexed citations

19.

Levallet, Guénaëlle, Emmanuel Bergot, Martine Antoine, et al.. (2012). High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway. Molecular Cancer Therapeutics. 11(5). 1203–1213. 74 indexed citations

20.

Moro‐Sibilot, Denis, et al.. (2007). Quel traitement pour un patient de PS-2/3 ayant un cancer bronchique non à petites cellules (CBNPC) de stade IV ?. Revue des Maladies Respiratoires. 24(8). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact